Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Methylprednisolone Plus Aneurysm Repair for Aneurysmal Subarachnoid Hemorrhage
ChiCTR2600118024Phase 4Not yet recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Jan 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in subarachnoid hemorrhage (SAH) comparing Placebo + standard treatment with Methylprednisolone sodium succinate + standard treatment (2 arms). Primary endpoints: Randomized 180-day good prognosis rate and Randomized mortality within 180 days. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
methylprednisolone
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on ChiCTR2600118024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118024.